Advanced Cell Technology (ACT) of Marlborough has announced a third site for the European clinical trial of its Stargardt’s Macular Dystrophy (SMD) treatment.
The treatment, which is derived from human embryonic stem cells, will be used at Scotland’s National Health Service provider Lothian. It will be used to determine the safety and tolerability of the cells following sub-retinal transplantation to patients with advanced SMD, which causes progressive vision loss in people ages 10 to 20.
The trial is similar to the company’s U.S. trials for SMD and dry age-related macular degeneration initiated in July 2011.
Read more
Marlborough Firm ACT Hails Stem Cell Ruling
ADVERTISEMENT
